Physician profile

Asima Ahmad

Reproductive Endocrinology · New Haven, CT

NPI 1679893069

$1,858.66

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

See the full distribution for Reproductive Endocrinology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$637.06
Travel and Lodging$530.14
Education$54.89

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Emd Serono, INC. $1,002.62 2019-2024
Ferring Pharmaceuticals INC. $491.82 2019-2024 Menopur, Endometrin
Organon LLC $168.89 2021-2024 Follistim Aq, Ganirelix Acetate, Pregnyl
Merck Sharp & Dohme LLC $141.52 2019-2021
Hologic Sales and Service, LLC $22.24 2024 Aptima
Abbvie INC. $19.24 2019
Avion Pharmaceuticals $12.33 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Asima Ahmad

$1,858.66

in general payments reported 2019-2025

Years
2019-2024
Top company
Emd Serono, INC.

https://glasscript.com/doctor/2790765/asima-ahmad

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.